Diverse and polymorphic killer cell immunoglobulin-like receptors (KIR) interact with highly polymorphic HLA class I ligands to regulate the development and effector functions of natural killer (NK) cells. The KIR gene family on human chromosome 19 varies In gene content and allelic polymorphism to give two distinctive forms of haplotype: A and B, that are the fundamental basis of KIR variability. We have shown for unrelated T-cell replete hematopoietic cell transplantations for acute myelogenous leukemia (AML) that the outcome of transplantation is significantly improved if the donor carries one or two KIR B haplotypes.
Aim 1 ofthe proposed investigation will perform genetic analysis, and study of further transplant cohorts, to assess the contribution of the telomeric and centromeric halves of the B haplotype to beneficial transplant outcome, and the role of the individual B haplotype specific genes and alleles.
Aim 2 will comJDare the HLA class I specificity and avidity of the various KIR isotypes and allotypes that distinguish A and B KIR haplotypes, with emphasis on B-specific KIR. This analysis will use a recently developed binding assay that is markedly more sensitive and reliable than previously used assays, and will examine the full range of HLA class I variation. The functional effects of positive binding reactions will be tested using an in vitro assay of cellular cytotoxicity in which single defined KIR variant interacts with a single defined HLA class I variant. Defined combinations of KIR will also be examined. The results from the functional analysis will be used, to develop rnore informed and new hypotheses, that will be tested by further retrospective analysis of the cohort of >1000 AML transplants studied in Aim 1. Thus the progress of investigation will logically move from bedside to bench and then back to bedside. This project will determine functional differences between the A and B haplotype KIR and determine which of these factors contribute to life-enhancing effect ofthe B haplotype in transplantation for acute myelogenous leukemia. The results should refine the genetic assessment of potential donors for transplantation, and thus improve the outcome of life-saying therapeutic transplantation for life-threatening leukemia.
This project will identify which NK cell receptors of donor origin are important for improving the outcome of transplantation as therapy for leukemia, and their mechanism of action. This knowledge will refine the selection of transplant donors and guide design of novel cellular therapy for leukernia.
|Presnell, S R; Al-Attar, A; Cichocki, F et al. (2015) Human natural killer cell microRNA: differential expression of MIR181A1B1 and MIR181A2B2 genes encoding identical mature microRNAs. Genes Immun 16:89-98|
|Cichocki, Frank; Schlums, Heinrich; Li, Hongchuan et al. (2014) Transcriptional regulation of Munc13-4 expression in cytotoxic lymphocytes is disrupted by an intronic mutation associated with a primary immunodeficiency. J Exp Med 211:1079-91|
|Cooley, Sarah; Weisdorf, Daniel J; Guethlein, Lisbeth A et al. (2014) Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia. J Immunol 192:4592-600|
|Bachanova, Veronika; Miller, Jeffrey S (2014) NK cells in therapy of cancer. Crit Rev Oncog 19:133-41|
|Foley, Bree; Felices, Martin; Cichocki, Frank et al. (2014) The biology of NK cells and their receptors affects clinical outcomes after hematopoietic cell transplantation (HCT). Immunol Rev 258:45-63|
|Miller, Jeffrey S; Rooney, Cliona M; Curtsinger, Julie et al. (2014) Expansion and homing of adoptively transferred human natural killer cells in immunodeficient mice varies with product preparation and in vivo cytokine administration: implications for clinical therapy. Biol Blood Marrow Transplant 20:1252-7|
|Felices, Martin; Lenvik, Todd R; Ankarlo, Dave E M et al. (2014) Functional NK cell repertoires are maintained through IL-2R? and Fas ligand. J Immunol 192:3889-97|
|Gleason, Michelle K; Ross, Julie A; Warlick, Erica D et al. (2014) CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets. Blood 123:3016-26|
|Sarkar, Chandrima; Cooley, Sarah; Srivastava, Jaideep (2014) Robust Feature Selection Technique using Rank Aggregation. Appl Artif Intell 28:243-257|
|Bachanova, Veronika; Cooley, Sarah; Defor, Todd E et al. (2014) Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein. Blood 123:3855-63|
Showing the most recent 10 out of 44 publications